Inspire Medical Systems, Inc. (NYSE:INSP) Shares Sold by Lmcg Investments LLC

Lmcg Investments LLC decreased its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 8.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,098 shares of the company’s stock after selling 2,794 shares during the period. Lmcg Investments LLC owned about 0.10% of Inspire Medical Systems worth $4,162,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. SouthState Corp purchased a new position in Inspire Medical Systems in the 2nd quarter valued at about $27,000. Daiwa Securities Group Inc. purchased a new position in Inspire Medical Systems in the 2nd quarter valued at $53,000. Principal Securities Inc. acquired a new stake in Inspire Medical Systems during the 4th quarter worth $54,000. Van ECK Associates Corp grew its holdings in shares of Inspire Medical Systems by 7.5% during the second quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock worth $138,000 after buying an additional 72 shares in the last quarter. Finally, RiverPark Advisors LLC raised its position in shares of Inspire Medical Systems by 360.1% in the first quarter. RiverPark Advisors LLC now owns 773 shares of the company’s stock valued at $166,000 after buying an additional 605 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, insider Randy Ban sold 4,861 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $188.55, for a total value of $916,541.55. Following the sale, the insider now directly owns 3,056 shares in the company, valued at $576,208.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Randy Ban sold 4,861 shares of Inspire Medical Systems stock in a transaction on Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the sale, the insider now directly owns 3,056 shares in the company, valued at approximately $576,208.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Shawn Mccormick sold 800 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now directly owns 23,140 shares of the company’s stock, valued at $5,090,800. The disclosure for this sale can be found here. In the last three months, insiders sold 5,692 shares of company stock valued at $1,099,207. Insiders own 4.10% of the company’s stock.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $207.95 on Tuesday. The firm has a market capitalization of $6.20 billion, a PE ratio of -378.09 and a beta of 1.33. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40. The firm’s 50-day moving average is $170.43 and its two-hundred day moving average is $181.29.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.46. The business had revenue of $195.89 million for the quarter, compared to analyst estimates of $189.08 million. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The company’s revenue was up 29.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.41) earnings per share. Analysts expect that Inspire Medical Systems, Inc. will post 0.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Morgan Stanley dropped their price objective on shares of Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Stifel Nicolaus cut their price target on Inspire Medical Systems from $210.00 to $170.00 and set a “hold” rating for the company in a report on Monday, June 24th. Robert W. Baird dropped their price objective on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a research note on Wednesday, August 7th. Finally, Bank of America dropped their price target on shares of Inspire Medical Systems from $225.00 to $185.00 and set a “neutral” rating for the company in a research note on Monday, June 3rd. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Inspire Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $214.85.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.